kpt-185 and Lymphoma--AIDS-Related

Infection with HIV ultimately leads to advanced immunodeficiency resulting in an increased incidence of cancer. For example primary effusion lymphoma (PEL) is an aggressive non-Hodgkin lymphoma with very poor prognosis that typically affects HIV infected individuals in advanced stages of immunodeficiency. Here we report on the dual anti-HIV and anti-PEL effect of targeting a single process common in both diseases. Inhibition of the exportin-1 (XPO1) mediated nuclear transport by clinical stage orally bioavailable small molecule inhibitors (SINE) prevented the nuclear export of the late intron-containing HIV RNA species and consequently potently suppressed viral replication. In contrast, in CRISPR-Cas9 genome edited cells expressing mutant C528S XPO1, viral replication was unaffected upon treatment, clearly demonstrating the anti-XPO1 mechanism of action. At the same time, SINE caused the nuclear accumulation of p53 tumor suppressor protein as well as inhibition of NF-κB activity in PEL cells resulting in cell cycle arrest and effective apoptosis induction. In vivo, oral administration arrested PEL tumor growth in engrafted mice. Our findings provide strong rationale for inhibiting XPO1 as an innovative strategy for the combined anti-retroviral and anti-neoplastic treatment of HIV and PEL and offer perspectives for the treatment of other AIDS-associated cancers and potentially other virus-related malignancies.

Topics: Acrylates; Active Transport, Cell Nucleus; Animals; Apoptosis; Base Sequence; Cell Cycle Checkpoints; Cell Line; Cell Nucleus; CRISPR-Cas Systems; Exportin 1 Protein; Female; HIV; Humans; Karyopherins; Lymphoma, AIDS-Related; Mice, Nude; Molecular Sequence Data; Molecular Targeted Therapy; NF-kappa B; Protein Binding; Receptors, Cytoplasmic and Nuclear; Reproducibility of Results; rev Gene Products, Human Immunodeficiency Virus; RNA, Messenger; RNA, Viral; Triazoles; Tumor Suppressor Protein p53; Virus Replication; Xenograft Model Antitumor Assays